House Wants FDA Action On Non-Pharma Pain Relievers, Breast Density Reports, Pediatric Devices In 2020
The US House Appropriations Committee wants the FDA to foster development of non-pharma and non-opioid pain alternatives, complete mammography breast density reporting regulations, and use an additional $1m Congress would provide to conduct pediatric device trials, among other device initiatives outlined in its 2020 budget bill passed on 4 June.
You may also be interested in...
The US House on 25 July signed off on a two-year budget deal for FY 2020 and 2021 raising the federal debt ceiling, and allowing funding for FDA and other federal agencies to go forward.
US House Passes FDA 2020 Budget In Minibus Bill, Moving It To Senate After $5M Boost In Telemedicine Funds
US appropriations legislation that would give the FDA’s device center an 8% raise over last year was passed by the US House on 25 June as part of a five-bill “minibus” package. It will move to the Senate for consideration after the US Independence Day recess. Among the last-minute amendments to H.R. 3055 was a $5m boost for telemedicine.
The US House completed work on the FDA portion of an appropriations “minibus” bill for 2020 on 20 June, agreeing to retain an approximate 8% increase for the agency’s device center.